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S214 Oral Presentationscomplications. We reports here 33 Korean PNH patients who un-
derwent allotransplantation.
Aims: To understand the impact of allotransplant in Korean PNH
patients, we retrospectively analyzed medical charts of 33 PNH pa-
tients from national registry in Korea.
Results: Patient ages ranged from 15 to 56 years (median 29 years,
male 14, female 19). Classic PNH were 12 patients and PNH with
bone marrow disease were 21. Median LDH level at the time of di-
agnosis was 1159 IU/L (297  7699). The source of stem cells were
bone marrow in 13 patients and peripheral blood in 20 patients. Sib-
ling donor were 23 and unrelated donor were 10. Conditioning reg-
imens consisted of BuCy or Cy/TBI (n5 14), fludarabine containing
reduced intensity regimen (n 5 18), or other. All patients attained
successful leukocyte engraftment (median 13 days, range 1030
days) and platelet engraftment (median 17 days, range 1148
days). Grade IIIV acute GVHD were in 19 patients (skin 13, liver
3, gut 3). Grade IIIV chronic GVHD were in 13 patients (limited
10, extensive 3). With a median follow-up of 82.6 months (range,
19.5 160.2 months), 26 patients are alive with CR. Seven patients
were died after transplantation due to pulmonary hemorrhage (n 5
2), sepsis (n 5 2), GVHD/multi organ failure n 5 2), or massive
thromboembolism (n 5 1). Patients with reduced intensity condi-
tioning regimen had a better survival than patients with conventional
conditioning regimen (p 5 0.027). There were no survival differ-
ences between classic PNH patients and PNH patients with BMD.
There were also no differences between two groups categorized by
PNH clone sizes, stem cell sources, and PNH related symptoms.
Conclusion: Our data demonstrates that reduced intensity condi-
tioning regimen is suitable for allogeneic stem cell transplatation
of PNH patients.31
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Nonmyeloablative conditioning with fludarabine (Flu) and 2 Gy
TBI with MMF/CSP postgrafting immunosuppression results in
reliable allogeneic engraftment. A retrospective analysis of pts
conditioned with 2 Gy TBI alone prior to receiving PBSC from
HLA-matched related donors showed that rejection primarily oc-
curred in pts who pre-HCT had not received intensive chemother-
apy. Addition of Flu (30 mg/m2/d x 3 d) in a subsequent cohort
seemed associated with increased nonrelapse mortality (NRM).
Here, we report results of a phase III randomized multi-institutional
trial that asked whether Flu was needed in heavily pretreated pts to
assure sustained engraftment of HLA-matched related grafts.
Immunosuppression included MMF (28 d) and CSP (180 d).
Eighty-five pts with AML (n 5 15), NHL (n 5 32), MM (n 5 9),
CLL (n 5 9), MDS (n 5 4), and HL (n 5 16) were randomized to
be conditioned with either 2 Gy TBI alone (TBI; n 5 44) or Flu/
2 Gy TBI (Flu/TBI; n5 41) with stratification by transplant center,
disease risk and prior high dose HCT. Pts received G-PBMC con-
taining a median of 7.9 x106 CD34 and 3.6 x108 CD3 cells/kg.
The median age was 55 (range, 17–73) years. Forty-five had failed
previous autologous (n 5 41) or allogeneic (n 5 4) high-dose
HCT. The primary endpoint was NRM with secondary endpoints
of survival, relapse/progression, GHVD and rejection. Median
follow-up was 4.6 (range, 0.6–7) years.Table. Transplant outcomes after HLA-matched related do-
nor HCT in patients conditioned with 2 Gy TBI only or with
fludarabine 90 mg/m2
TBI Flu/TBI(n 5 44) (n 5 41) PRejections (number of pts) 2 0 0.50GVHD Grade II-IV acute @ 120 d, % 34 46 0.23Grade III-IV acute @ 120 d, % 9 7 0.82Chronic @ 3 years 49 71 0.21Donor
chimerismT-cell day 28, %, median 61 90 <0.0001T-cell day 84, %, median 68 92 <0.0001NK-cell day 28, %, median 75 96 0.0005Nonrelapse mortality @ 3 years, % 17 14 0.35Relapse/progression @ 3 years, % 51 33 0.04Relapse mortality @ 3 years, % 32 22 0.10Overall survival @ 3 years, % 52 65 0.09Progression-free survival @ 3 years, % 32 53 0.03No significant differences between arms were observed for NRM
(3 year; TBI 17%, Flu/TBI 14%), grade II-IV acute (TBI 34%, Flu/
TBI 46%) or chronic GVHD (TBI 49%, Flu/TBI 71%). Rejection
was only observed in 2 TBI pts. The 3 year survival was 52% and
65% in TBI and Flu/TBI pts (p 5 0.09), respectively, with a higher
incidence of relapse/progression (TBI 51%, Flu/TBI 33%, p5 0.04)
and relapse related mortality (TBI 32%, Flu/TBI 22%, p 5 0.10),
translating into a significantly lower progression-free survival (TBI
32%, Flu/TBI 53%, p 5 0.03) in TBI pts. Compared to TBI pts,
the CD3 donor chimerisms on d28 and d84 were significantly higher
in Flu/TBI pts as was the NK cell chimerism on d28. Even though
low rates of rejection and similar incidences of NRM were observed
in both arms, Flu/TBI pts had better progression free survival. In
view of the significantly higher CD3 and NK donor chimerism in
Flu/TBI pts, the result of this randomized trial demonstrate the im-
portance of Flu in augmenting the graft versus tumor effect, by en-
suring prompt and durable high level donor engraftment early
post-transplant.
32
ADENOVIRUS VIREMIA IN PATIENTS WITH CLINICAL SYMPTOMS AFTER
T-CELL DEPLETED HSCT: RATES OF ADENOVIRUS DISEASE AND OUT-
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Background: Invasive ADV infections are a known cause of mortal-
ity in HSCT.High or rising ADV viral loads are thought to be a pre-
dictor of ADV disease. T-cell depletion (TCD) reduces the risk of
graft vs host disease, but has been associated with an increased inci-
dence and complications of certain viral infections.We examined the
outcomes of patients found to have ADV viremia after TCDHSCT
at our institution.
Method: A retrospective review was conducted on 401 adult and pe-
diatric patients who received TCD HSCTs at MSKCC from Jan
2006 through March 2011. Follow up ranged from (6 months - 5
years). Quantitative ADV PCR in whole blood was evaluated by
the treating physicians based on clinical symptoms. ADV viremia
was defined as at least 1 positive study of $ 1,000 copies/ml or .2
consecutive positive studies of $500 copies/ml/ ADV PCR. Defini-
tions were: early ADV viremia - first positive ADV PCR at\ 180
days post HSCT, and high viral load (HVL) as $ 10,000 copies/
ml. ADV Disease: Definite: presence of typical adenovirus nuclear
inclusions on histopathology, and/or positive culture from sterile
site (other than blood), or both. Probable adenovirus: ADV viremia
and associated clinical symptoms without other identifiable causes).
Results: The 401 TCD HSCTs included 23.7% children, 90% pe-
ripheral blood stem cell grafts, and 63.1% unrelated donors, median
age 47.5 yrs (range 0.1-73 yrs). Thirty five (8.7%) patients were di-
agnosed with ADV viremia at a median of 93 days (range 15 - 674)
post HSCT. The incidence of diagnosed ADV viremia in this group
was higher in pediatric vs adult pts (15.3 vs 6.2%). ADVwas detected
in 35/401 (8.7%) (6.2% adult and 15.3% pediatric) pts a median of
Oral Presentations S21593 days (range 15 - 674) post HSCT. Fourteen (40%) were deter-
mined to have invasive ADV disease (7 on tissue biopsy). ADV viral
load evaluation over time revealed the following: HVL at presenta-
tion in 18 (51.4%) (median 1.1x104,range 7.4x105 - 6.8x109 copies/
ml); 10 (28%) progressed to HVL (median 2 log increase from pre-
sentation) at a median of 15 days (range 3 - 56); and LVL-only at any
time point in 7 (20%) pts (median 4000 copies/ml, range 600 - 8866).
Fifteen pts with HVL were treated with cidovofir intravenously or/
and CMX001 a median 7 doses (range 1 - 38). Despite treatment
with antiviral therapy 12 pts (92%) with HVL and 7 pts (87.5%)
with LVL-HVL died. Mortality was attributable to ADV in 11
(31.4%) pts. All cause 180 day mortality was 74.3% for pts with
ADV.
Conclusions: ADV viremia was relatively low (8.7%) in this high
risk population and similar to the 5% reported in populations receiv-
ing conventional transplants. Determination of viral status in pa-
tients with clinical symptoms resulted in a relatively high yield of
positivity - 40%. Themortality attributable to ADVof 30% suggests
the need for development of better treatment modalities. The 180
day all cause mortality of 74% suggests ADV viremia complicates
other medical conditions and complications of transplant.
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COINFUSION OF HAPLO-IDENTICAL DONOR STEM CELLS WITH AN (UN)
RELATED CORD TRANSPLANT PROVED TO BE SUCCESSFUL IN A VERY
HIGH RISK GROUP OF PATIENTS
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Introduction: Combining haplo-donor stem cells with a full graft
cord blood (CB)-unit has been proposed as a cell support mechanism
which can make single CB available as a donor source for allogeneic
HSCT to a larger proportion of patients: e.g. patients with only do-
nors available with low NC-counts, or with active infections.
Methods: Since 2009 we have a CB+haplo protocol for this group of
patients. Patients (with any indication) with active infection (e.g. fun-
gal) as well as patients with only a CB-unit available below the lower
acceptable cut off were offered a CB+Haplo grafting. All patients re-
ceived myeloablative conditioning (busulfan with therapeutic drug
monitoring in combination with either CY or FLU) and serotherapy
(ATG 8, Campath 1). Haplo-grafts were CD34+ selected (except 1:
CD3/CD19 negative selected). After infusion of the CB, the haplo-
graft containing 5milj/kg CD34+ cells were infused. G-CSF was
given from day +7. GvHD prophylaxis: CsA+pred 1mg/kg.
Results.: 9 patients (8 children, 1 adult; 8 with active infection, 1 low
cell count CBU). Median age was 12.4 yr (range 0.25-41.2 yr). 7 had
a non-malignant disease (5 immunodeficiencies, 1 Osteopetrosis, 1
AA), 2 had a malignant indication. For 2 patients it was their second
transplant. All patients except 1 engrafted at a median time of 12 days
(range 9-15). Thrombocyte engraftment (TBC50) was 36 days
(range14-300). EFS was 33% after a median follow up 249 days
(14-1245). Incidence of GvHD gr. 2-4 was 25%. The non-relapse
mortality was 2/9 (day 14 and day 24 respectively).The initial donor
chimerism at 1 month post SCT showed.80% haplo chimerism in
most patients but all 7 reached a full donor cord blood chimerism
(.95%) within a median period of 121 days (28-925 days) post SCT.
Conclusion: Coinfusion of Haplo with (unrelated) CB transplanta-
tion is a safe and effective option for a group of very high risk patients
(including patients with higher non-engraftment risks) to secure
early engraftment. Haplo-support leads to early haplo-engraftment
switching to full CB donor-chimerism within 4 months, allowing
a normal immune recovery and repertoire.34
CD8-DEPLETED DONOR-LYMPHOCYTE INFUSIONS AFTER T-CELL DE-
PLETED ALLOGENEIC HEMOPOIETIC STEM CELL TRANSPLANTATION
Wagner, E.M., Wehler, D., Kolbe, K., Theobald, M., Herr, W.,
Meyer, R.G. University Medical Center of the Johannes Gutenberg-Uni-
versity, Mainz, Germany
In a phase I/II clinical trial, we investigated the prophylactic use of
CD8-depleted (CD8depl) donor lymphocyte infusions (DLI) in thesetting of T-cell depleted allogeneic hematopoietic stem cell trans-
plantation (HSCT). T-cell depletion was carried out by the use of
high-dose Alemtuzumab (100 mg or 60 mg for unrelated or sibling
donor transplantation, respectively). Here, we provide clinical fol-
low-up data of 101 patients with different hematologic diseases
and a median observation time of 1.5 years (range, 6-84 months).
Median age was 56 years (range, 20-71). Stem cell source were pe-
ripheral blood stem cells of matched siblings (n 5 15), matched un-
related (n 5 48), or unrelated donors with single HLA mismatches
(n5 38). Tapering of Cyclosporin A was started in the 6th week after
transplantation. Subsequently, CD8depl DLI were administered pro-
phylactically in escalating doses starting with 1x106 CD4 T cells/kg
bodyweight. 39 patients received at least one dose of DLI. Among
patients who did not qualify for DLI, 46 patients had primary
GVHD. In 16 patients DLI were not administered for other reasons.
Following DLI, acute GVHDwas the major reason for withholding
subsequent DLI-doses (64%) and 30% suffered from acute GVHD
\ 2. Extensive chronic GVHD was diagnosed in 10% of the pa-
tients. The 1 and 3 year overall survival was 63% and 43%, respec-
tively. Survival significantly differed between the DLI and non
DLI group after 3 years (62% vs. 27%, p 5 0.002). When the DLI
group was compard to those patients who did not receive DLI for
other reasons than primary GVHD, the difference in overall survival
was similar (62% vs. 28%, p5 0.01). The presence of GVHD at any
time was associated with a reduced relapse rate (56% vs. 31%, p 5
0.013), independent of DLI.We demonstrated that 21 of 24 patients
(84%)with decreasingT-cell chimerism (TCC) converted to full do-
nor following CD8depl DLI. In contrast, only 2 of 8 patients (25%)
with decreasing TCC in the non-DLI group converted spontane-
ously.
In summary, we observed that the application of prophylactic
CD8depl DLI was associated with a survival benefit – even though
the nature of the trial does not argue for a causal relationship. Our
data strongly ask for randomized trials either comparing prophylac-
tic application of CD8depl DLI vs. no DLI or CD8depl vs. non-ma-
nipulated DLI in a preemptive setting.35
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Background: The most important mechanism for natural protec-
tion against HIV transmission is a mutation in the CCR5 gene lead-
ing to a 32-base-pair deletion (CCR5-delta32) and a non-functional
CCR5 protein. Prior to 2001, Chow et al pioneered the concept to
screen allogeneic stem cell donors for those homozygous for
CCR5-delta32 to transplant HIV infected patients (U.S. patent
2003/0099621 A1), as acknowledged by Hutter et al recently (The-
ScientificWorld Journal, 2011;11:1068-1076). Hutter et al (NEJM
2009;360:692-698) performed a bone marrow transplant in a patient
with acute leukemia who was infected with HIV using a donor ho-
mozygous for the CCR5-delta32 deletion. More than 4 years later
the patient does not require antiretrovial therapy and no viral load
or proviral DNA can be detected. However, this procedure cannot
be generalized using adult donors because the variant allele is quite
unusual (\1% of Caucasians, and much lower in other ethnic
groups) and a very close HLA match is required between adult do-
nors and patients.
Hypothesis: Cord blood HCT requires HLA matching of only 4 of
6 alleles. Therefore, our hypothesis is that an inventory of cord blood
